{'fraction_non_alphanumeric': 0.021136063408190225, 'fraction_numerical': 0.008586525759577279, 'mean_word_length': 5.763392857142857, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The identification and characterization of Glucagon‐like Peptide‐1 receptors on rat peripheral nerves

Peripheral neuropathy, a common neurological disorder and a major cause of neuropathic pain, results in negative symptoms such as thermal hypoalgesia, loss of pain sensation, undetected infections and limb amputations, and positive symptoms such as burning and stabbing pain. The well established sciatic nerve injury model exhibits an equivalent capacity of regeneration in rats compared to subhuman primates. Glucagon‐like peptide 1 (GLP‐1), an incretin hormone secreted from the enteroendocrine L cells in distal ileum and colon, increases circulating postprandial insulin levels. While it has been reported that GLP‐1 exhibits neuroprotection, no studies have yet been undertaken to identify GLP‐1 receptors on peripheral nerves. Therefore, it is unknown whether GLP‐1's beneficial effects are through a direct action on the nerves or indirectly through elevated insulin levels. We performed immunoblotting assays using a rabbit polyclonal antibody to the GLP‐1 receptor. A 34kDa protein band was detected in homogenates of rat peripheral sciatic nerves and rat insulinoma RINm5F cells known to express the GLP‐1 receptor. Future studies will characterize GLP‐1 receptors on sciatic nerve and evaluate the effects of GLP‐1 on neurobehavioral aspects of neuropathy caused by neurotrauma and conditions like diabetes. These findings may aid in the development of potential therapies for peripheral neuropathy.